TenQ · fact sheet · filings current to · price as of
Thermo Fisher Scientific (TMO)
A mixed picture - strengths and real weaknesses - 26 of 36 checks passed.
Latest close : $613.78, -0.8% on the day; -3.8% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $613.78 |
| Market cap | $226.9B |
| 52-week range | $437.90 - $638.18 |
| P/E | 33.2x |
| P/E, own 11-year median | 29.8x |
| P/S | 4.9x |
| Free cash flow yield | 3.2% |
| Dividend yield | 0.3% |
| Revenue (TTM) | $46.3B |
| Net income (TTM) | $7.0B |
| Free cash flow (TTM) | $7.3B |
| Gross margin | 24.4% |
| Operating margin | 17.6% |
| Return on equity | 13.3% |
| Revenue growth (1y) | +7.2% |
| Revenue CAGR (3y) | -0.3% |
| Debt / equity | 0.87x |
| Cash & short-term investments | $4.1B |
| Shares outstanding | 369.7m (cover page of the latest filing, 2026-06-27) |
The score: 26 of 36 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is TMO stock cheap or expensive right now?
Value · 1 of 6 checks passed. Expensive against its own history and its sector - you're paying up for what you get. chapter →
Is Thermo Fisher Scientific still growing?
Growth · 3 of 6 checks passed. Growing, but with caveats - revenue +7.2% over the last year. chapter →
Does Thermo Fisher Scientific make real money?
Quality · 4 of 6 checks passed. A solidly profitable business, though not exceptional against its sector. chapter →
Can Thermo Fisher Scientific survive a bad year?
Health · 6 of 6 checks passed. A fortress balance sheet - TMO can survive a very bad year. chapter →
What does Thermo Fisher Scientific hand back to shareholders?
Shareholder returns · 6 of 6 checks passed. Owners are paid reliably and the share count is not eroding their stake - though the dividend itself is a token. chapter →
Which way is TMO trending?
Trend analysis · 6 of 6 checks passed. The market agrees: the stock is in a healthy uptrend on every horizon. chapter →
Are insiders buying or selling TMO?
Open-market buys: $0.00 · sells: $38M, across the recent Form 4 filings. detail →
Other instruments and medical devices we cover: Intuitive Surgical (ISRG) · DexCom (DXCM) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.